Autolus reports strong Q3 2026 net product revenue of $41.2M, up 95% YoY
Autolus Therapeutics reported strong Q3 revenue growth for AUCATZYL, raising full-year guidance to at least $150 million, supported by expanding market access and manufacturing efficiency initiatives.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed